NASDAQ · HSCS
HeartSciences Inc.
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.2% below the high.
Loading market information…
NASDAQ · SHPH · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Shuttle Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Shuttle Pharmaceuticals Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.2% below the high.
$1.38-$0.08 (-5.48%)
BioVie Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.59% below the high.
$0.19-$0.00 (-1.53%)
Theriva Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.99% below the high.
$1.10+$0.03 (+2.8%)
Akanda Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.61% below the high.
$0.79-$0.08 (-9.35%)
iSpecimen Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.6% below the high.
$0.39-$0.00 (-0.94%)
Bone Biologics Corporation’s quoted price sits in the lower half of its reported 52-week range, 83.75% below the high.
$0.42-$0.01 (-2.66%)
RedHill Biopharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 73.96% below the high.
$1.54-$0.39 (-20.21%)
Universe Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.43% below the high.
